What was the overall market valuation of the GCC insulin biosimilars market in 2024?

The overall market valuation was $0.139 Million in 2024. Read More

What is the projected market valuation for the GCC insulin biosimilars market by 2035?

The projected valuation for 2035 is $0.301 Million. Read More

What is the expected CAGR for the GCC insulin biosimilars market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 7.28%. Read More

What are the segment valuations for rapid-acting biosimilars in the GCC market?

The segment valuation for rapid-acting biosimilars ranged from $0.045 Million to $0.095 Million. Read More

What is the valuation range for long-acting biosimilars in the GCC insulin biosimilars market?

The valuation for long-acting biosimilars ranged from $0.065 Million to $0.135 Million. Read More

What is the valuation range for premixed biosimilars in the GCC market?

The valuation for premixed biosimilars ranged from $0.029 Million to $0.071 Million. Read More

What are the segment valuations for Type I and Type II diabetes in the GCC insulin biosimilars market?

Type I diabetes had a valuation range of $0.0695 Million to $0.149 Million, while Type II diabetes ranged from $0.0695 Million to $0.152 Million. Read More

How does the GCC insulin biosimilars market's growth compare to other regions?

While specific comparisons to other regions are not provided, the GCC market is poised for growth with a projected CAGR of 7.28%. Read More

What factors may influence the growth of the GCC insulin biosimilars market?

Factors such as increasing diabetes prevalence and advancements in biosimilar technology may influence market growth. Read More

GCC Insulin Biosimilars Market

Q: Which companies are considered key players in the GCC insulin biosimilars market?

Key players include Sanofi, Boehringer Ingelheim, Mylan, Sandoz, Teva, Fresenius Kabi, Celltrion, Amgen, and Roche. Read More

ID: MRFR/MED/49868-HCR

200 Pages

Vikita Thakur

Last Updated: April 06, 2026

GCC Insulin Biosimilars Market Research Report By Type (Rapid-acting biosimilars, Long-acting biosimilars, Premixed biosimilars) and By Indication (TYPE I DIABETES, TYPE II DIABETES) - Growth & Industry Forecast 2025 To 2035

GCC Insulin Biosimilars Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)7.28%

2024 Market Size$ 0.14 Million

2025 Market Size$ 0.15 Million

2035 Market Size$ 0.3 Million

Key Players

Sanofi

Boehringer Ingelheim

Mylan

Sandoz

Teva

Fresenius Kabi

Trends

Regulatory Advancements
Rising Demand for Cost-Effective Solutions
Increased Awareness and Education

Opportunities

Cost-Containment Initiatives
Growing Prevalence of Diabetes
Regulatory Support for Biosimilars

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Type (USD Million)
  1. 4.1.1 Rapid-acting biosimilars
  2. 4.1.2 Long-acting biosimilars
  3. 4.1.3 Premixed biosimilars
2. 4.2 Healthcare, BY Indication (USD Million)
  1. 4.2.1 Type I Diabetes
  2. 4.2.2 Type II Diabetes
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Sanofi (FR)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Boehringer Ingelheim (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Mylan (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Sandoz (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Teva (IL)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Fresenius Kabi (DE)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Celltrion (KR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Amgen (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Roche (CH)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 GCC MARKET ANALYSIS BY TYPE
3. 6.3 GCC MARKET ANALYSIS BY INDICATION
4. 6.4 KEY BUYING CRITERIA OF HEALTHCARE
5. 6.5 RESEARCH PROCESS OF MRFR
6. 6.6 DRO ANALYSIS OF HEALTHCARE
7. 6.7 DRIVERS IMPACT ANALYSIS: HEALTHCARE
8. 6.8 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
9. 6.9 SUPPLY / VALUE CHAIN: HEALTHCARE
10. 6.10 HEALTHCARE, BY TYPE, 2024 (% SHARE)
11. 6.11 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Million)
12. 6.12 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
13. 6.13 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Million)
14. 6.14 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 GCC MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY INDICATION, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

GCC Insulin Biosimilars Market Segmentation

GCC Insulin Biosimilars Market By Type (USD Million, 2025-2035)

Rapid-acting biosimilars
Long-acting biosimilars
Premixed biosimilars

GCC Insulin Biosimilars Market By Indication (USD Million, 2025-2035)

Type I Diabetes
Type II Diabetes

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”